Intra-Cellular Therapies, Inc.

DB:23I Stock Report

Market Cap: €8.6b

Intra-Cellular Therapies Valuation

Is 23I undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 23I when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 23I (€81) is trading below our estimate of fair value (€534.59)

Significantly Below Fair Value: 23I is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 23I?

Key metric: As 23I is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 23I. This is calculated by dividing 23I's market cap by their current revenue.
What is 23I's PS Ratio?
PS Ratio14.8x
SalesUS$613.73m
Market CapUS$9.08b

Price to Sales Ratio vs Peers

How does 23I's PS Ratio compare to its peers?

The above table shows the PS ratio for 23I vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
BAYN Bayer
0.4x1.0%€19.0b
DMP Dermapharm Holding
1.6x4.1%€1.9b
MRK Merck KGaA
2.9x4.1%€61.6b
PSG PharmaSGP Holding
2.7x7.3%€304.6m
23I Intra-Cellular Therapies
14.8x33.6%€9.1b

Price-To-Sales vs Peers: 23I is expensive based on its Price-To-Sales Ratio (14.8x) compared to the peer average (1.9x).

Price to Sales Ratio vs Industry

How does 23I's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 CompaniesPrice / SalesEstimated GrowthMarket Cap
23I 14.8xIndustry Avg. 2.9xNo. of Companies33PS0612182430+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 23I is expensive based on its Price-To-Sales Ratio (14.8x) compared to the European Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is 23I's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

23I PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio14.8x
Fair PS Ratio10.1x

Price-To-Sales vs Fair Ratio: 23I is expensive based on its Price-To-Sales Ratio (14.8x) compared to the estimated Fair Price-To-Sales Ratio (10.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 23I forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€81.00
€96.26
+18.8%
12.9%€127.58€74.66n/a15
Nov ’25€78.50
€92.68
+18.1%
14.4%€124.12€72.63n/a15
Oct ’25€65.00
€86.57
+33.2%
14.5%€117.07€66.64n/a15
Sep ’25€65.00
€84.76
+30.4%
16.5%€116.56€60.97n/a15
Aug ’25€72.50
€86.51
+19.3%
15.4%€110.59€59.90n/a15
Jul ’25€63.50
€85.97
+35.4%
15.5%€112.02€60.68n/a16
Jun ’25€60.50
€84.23
+39.2%
15.0%€111.56€60.43n/a16
May ’25€67.50
€84.34
+24.9%
15.0%€112.10€60.72n/a17
Apr ’25€64.00
€75.91
+18.6%
11.7%€92.25€59.37n/a17
Mar ’25€65.40
€76.91
+17.6%
12.1%€93.33€60.07n/a16
Feb ’25€62.70
€74.19
+18.3%
14.4%€93.18€54.43n/a16
Jan ’25€66.00
€70.73
+7.2%
16.5%€92.01€52.84n/a15
Dec ’24€56.70
€72.31
+27.5%
17.6%€94.19€54.09n/a13
Nov ’24€47.10
€72.96
+54.9%
16.4%€94.19€55.57€78.5013
Oct ’24€50.80
€71.48
+40.7%
16.2%€90.87€53.61€65.0012
Sep ’24€50.90
€71.48
+40.4%
16.2%€90.87€53.61€65.0012
Aug ’24€55.90
€70.35
+25.8%
14.8%€88.67€53.38€72.5012
Jul ’24€57.00
€70.56
+23.8%
15.7%€89.81€53.15€63.5012
Jun ’24€54.60
€68.24
+25.0%
16.8%€89.07€52.72€60.5013
May ’24€55.60
€66.52
+19.6%
16.6%€88.74€50.71€67.5013
Apr ’24€50.88
€65.50
+28.7%
18.3%€90.41€51.66€64.0013
Mar ’24€45.69
€65.58
+43.5%
17.1%€87.22€49.71€65.4013
Feb ’24€44.40
€64.53
+45.3%
17.1%€85.74€49.78€62.7013
Jan ’24€49.42
€68.95
+39.5%
17.6%€93.34€50.19€66.0013
Dec ’23€51.48
€68.95
+33.9%
17.6%€93.34€50.19€56.7013
Nov ’23€46.87
€67.22
+43.4%
17.4%€89.27€48.60€47.1013

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%